Clinical trials: HFpEF - Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction
Beta blockers have been used to reduce the mortality and heart failure rehospitalization in heart failure with reduced ejection fraction (HFrEF) patients in addition to ACEI/ARB, MRA, ivabradine and ARNI.
- Trial name
- NCT03948685
- Testing
- Carvedilol SR
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Yonsei University
Heart Failure, Preserved Ejection Fraction
Readmission Risk Factors and Heart Failure With Preserved Ejection Fraction
Retrospective review of 492 patient from a small community hospital who did not qualify for participation in the Connect HF study sponsored by DCRI.
- Trial name
- NCT04008914
- Testing
- retrospective observation
- Where
- United States
- Volunteers
- 492 people
- Sponsor
- Ascension Macomb-Oakland Hospital
Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction
The goal of this clinical trial is to test an experimental gene therapy in participants with heart failure with preserved ejection fraction, also known as diastolic heart failure.
- Trial name
- MUSIC-HFpEF (NCT06061549)
- Testing
- AAV1/SERCA2a
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Sardocor Corp.